Trials / Recruiting
RecruitingNCT06730659
A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors
A Single-Arm, Open-Label, Phase I Study of CHT101 for CD70-Positive Relapsed/Refractory Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive advanced solid tumors.
Detailed description
4 planned dose cohorts will be evaluated during dose escalation phase. The dose expansion will be initiated after SRC (safety review committee) review the avaliable safety, PK and preliminary efficacy data.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CHT101 | CHT101: CD 70 UCAR T |
Timeline
- Start date
- 2024-04-19
- Primary completion
- 2027-04-18
- Completion
- 2039-04-18
- First posted
- 2024-12-12
- Last updated
- 2024-12-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06730659. Inclusion in this directory is not an endorsement.